{"entity":{"id":"nct06616389","kind":"trial","name":"Study of ODX (OsteoDex) in Multiple Myeloma","aka":[],"tldr":"A phase 1/2 trial of ODX (Osteodex) in multiple myeloma, run by DexTech Medical AB, now recruiting.","summary":"Study of ODX (OsteoDex) in Multiple Myeloma is a phase 1/2 interventional study registered as NCT06616389 by DexTech Medical AB, with 12 participants planned, started 2023-11-29 and due to reach its primary completion in 2026-01-30. Interventions recorded: ODX (Osteodex).","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06616389","url":"https://clinicaltrials.gov/study/NCT06616389"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06616389","phase":"1/2","setting":"A Phase I/IIa Study of ODX (OsteoDex) in Multiple Myeloma","sponsor":"DexTech Medical AB","enrolled":12,"outcomes":[]},"route":"/trials/nct06616389/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}]}}